Piramal Pharma is a global pharmaceutical company with a presence in over 100 countries. It is headquartered in Mumbai, India. The company has three main businesses:
- Piramal Pharma Solutions: This is a contract development and manufacturing organization (CDMO) that provides services to pharmaceutical and biotechnology companies. Piramal Pharma Solutions offers a wide range of services, from drug discovery to commercial manufacturing.
- Piramal Critical Care: This business produces inhaled anesthetics and other critical care products. It is a leading player in the hospital generics market.
- Consumer Healthcare:Â This business sells over-the-counter (OTC) products in India.
Piramal Pharma Overview
| Description | Details |
|---|---|
| Headquarters | Global pharmaceutical company |
| Business Segments | Mumbai, India |
| CDMO, Critical Care, Consumer Healthcare | |
| Piramal Pharma Solutions | Contract development and manufacturing |
| Drug discovery to commercial manufacturing | |
| Piramal Critical Care | Inhaled anesthetics, Critical care products |
| Leading player in hospital generics market | |
| Consumer Healthcare | OTC products in India |
Piramal Pharma Products
| Category | Brand | Description |
|---|---|---|
| Skin Care | Lacto Calamine Oil Balance Lotion | Lightweight lotion, controls oil & shine, fresh & hydrated skin. |
| Lacto Calamine Face Wash | Gentle face wash, removes impurities, hydrated skin. | |
| Lacto Calamine Face Scrub | Exfoliating face scrub, removes dead skin cells, smooth & refreshed skin. | |
| Antacids | Polycrol | Antacid tablet, fast relief from indigestion & heartburn. |
| Digestives | Digeplex | Digestive enzyme supplement, breaks down food, improves digestion. |
| Women’s Health | i-pill | Emergency contraceptive pill, prevents pregnancy after unprotected sex. |
| Kids’ Wellbeing & Baby Care | Jungle Magic Kids Range | Cough syrups, pain relievers, vitamins for kids. |
Piramal Pharma Awards and Recognition
| Year | Award | Category | Awarded To |
|---|---|---|---|
| 2023 | Business Leader of the Year | Business Leadership | Mr. Ajay Piramal, Chairman, Piramal Group |
| 2022 | OTC Company of the Year | Pharmaceuticals | Piramal Pharma Limited |
| 2022 | Winner in 6 Categories Across Small Pharma | CMO Leadership | Piramal Pharma Solutions |
| 2021 | 2021 Global Contract Development and Manufacturing Organization Customer Value Leadership Award | Customer Service | Piramal Pharma Solutions |
| 2020 | Best Contract Manufacturing (CMO) Provider | Contract Manufacturing | Piramal Pharma Solutions |
| 2019 | Frost & Sullivan Global Customer Service Leadership Award | Customer Service | Piramal Pharma Solutions |
| 2018 | Excellence in Contract Research and Manufacturing | Pharmaceuticals | Piramal Pharma Solutions |
| 2018 | CII South Region EHS Excellence Award | Environment, Health & Safety | Piramal Pharma Solutions (Ennore facility) |
Piramal Pharma Fundamentals
| Metric | Value | Description |
|---|---|---|
| Market Capitalization (INR) | 18,369.13 Cr | The total market value of the company’s outstanding shares. |
| Revenue (INR) | 1,911.38 Cr (Consolidated) | Gross income from a company’s core business operations. |
| EBITDA (INR) | 573.46 Cr (Consolidated) | Earnings before interest, taxes, depreciation, and amortization, a measure of a company’s profitability before financing and accounting decisions. |
| EPS (INR) | 1.02 (Standalone) | Earnings per share, the portion of a company’s profit allocated to each outstanding share of common stock. |
| P/E Ratio | 220.62 (Standalone) | The price-to-earnings ratio, a measure of a company’s relative valuation based on its current stock price and its earnings per share. |
| P/B Ratio | 7.70 (Standalone) | The price-to-book ratio, a measure of a company’s relative valuation based on its current stock price and its book value per share. |
| Dividend Yield | N/A | The annual dividend paid out as a percentage of the current stock price. Piramal Pharma did not declare any dividends for the FY ending March 31, 2023. |
| Debt/Equity Ratio | 0.24 (Consolidated) | The ratio of a company’s total debt to its total shareholders’ equity, a measure of a company’s financial leverage. |
| Book Value (INR) | 47.95 (Standalone) | The total value of a company’s assets minus its liabilities, representing the owners’ equity. |
| Face Value (INR) | 10 | The par value of each share of the company’s stock. |
| ROE (Standalone) | 1.34% | The return on equity, a measure of a company’s profitability relative to its shareholders’ equity. |
| Debt (INR) | 4,407.52 Cr (Consolidated) | The total amount of money a company owes to creditors. |
Piramal Pharma Revenue and Net Profit
| Period | Revenue | Net Profit | YoY Revenue Growth | YoY Net Profit Growth |
|---|---|---|---|---|
| Latest Reported Quarter (Q3 FY24) | N/A | N/A | N/A | N/A |
| Q2 FY24 | N/A | N/A | N/A | N/A |
| Q1 FY24 | N/A | N/A | N/A | N/A |
| FY23 | 3,443.22 | 69.50 | 15.2% | -79.2% |
| Q4 FY23 | 2,164.00 | 50.00 | 1.0% | -75.0% |
| Q3 FY23 | 1,911.38 | 57.18 | 11.1% | -66.2% |
| Q2 FY23 | 1,748.85 | 65.69 | 18.0% | -62.7% |
| Q1 FY23 | 1,630.99 | 72.64 | 16.9% | -55.4% |
| FY22 | 2,977.57 | 343.05 | 14.2% | 47.9% |
Piramal Pharma Shareholding Patterns
| Shareholder Category | Holding % | Number of Shares (Cr.) | Notes |
|---|---|---|---|
| Promoters (Piramal Enterprises Ltd.) | 35.02% | 564.27 | Controlling shareholder |
| Foreign Institutional Investors (FIIs) | 32.37% | 518.52 | Includes foreign portfolio investors and mutual funds |
| Domestic Institutional Investors (DIIs) | 3.80% | 60.80 | Includes mutual funds, insurance companies, and banks |
| Public/Retail Shareholders | 28.81% | 463.41 | Individual investors and small institutions |
Piramal Pharma Share Price Target for 2025, 2026, 2027, 2028, 2029
| Year | Estimated Share Price (INR) |
|---|---|
| 2025 | 154 |
| 2026 | 184 |
| 2027 | 220 |
| 2028 | 264 |
| 2029 | 316 |
Piramal Pharma Share Price Target for 2025
Piramal Pharma Share Price Target for 2025 is 154.
Piramal Pharma Share Price Target for 2026
Piramal Pharma Share Price Target for 2026 is 184.
Piramal Pharma Share Price Target for 2027
Piramal Pharma Share Price Target for 2027 is 220.
Piramal Pharma Share Price Target for 2028
Piramal Pharma Share Price Target for 2028 is 264.
Piramal Pharma Share Price Target for 2029
Piramal Pharma Share Price Target for 2029 is 316.
Piramal Pharma Dividend History
| Year | Dividend Type | Dividend per Share (INR) | Dividend Yield (%) | Ex-Dividend Date |
|---|---|---|---|---|
| 2022-2023 | Final | N/A | N/A | N/A |
| 2021-2022 | Final | 33.00 | 3.32 | July 16, 2022 |
| 2020-2021 | Final | 33.00 | 3.32 | July 21, 2021 |
| 2019-2020 | Final | 14.00 | 1.40 | July 17, 2020 |
| 2018-2019 | Final | 28.00 | 2.80 | July 19, 2019 |
| 2017-2018 | Final | 25.00 | 2.50 | July 21, 2018 |
| 2016-2017 | Final | 21.00 | 2.10 | July 20, 2017 |
| 2015-2016 | Interim | 17.50 | 1.75 | July 17, 2016 |
Future Outlook of Piramal Pharma
Positive Signals:
-
Strong growth potential: Analysts forecast robust revenue and earnings growth for Piramal Pharma in the next few years, driven by several factors:
- Booming CDMO market: The CDMO segment, Piramal’s core business, is expected to see sustained growth due to increasing outsourcing trends in the pharmaceutical industry.
- Expansion in Hospital Generics and Consumer Healthcare: Piramal is actively expanding these segments, which offer promising growth opportunities.
- Strong R&D pipeline:Â The company’s focus on developing niche and complex generics could boost its margins and competitiveness.
Read more:
Risks Associated With Investing in Piramal Pharma
| Category | Risk Description | Potential Impact | Mitigation Strategies |
|---|---|---|---|
| Competition: | Intense competition in the CDMO market from established players & new entrants | Lower market share, reduced profitability | Strengthen competitive advantages through cost-efficiency, quality, & diverse service offerings. Monitor and adapt to competitor strategies. |
| Economic Uncertainties: | Global economic fluctuations and geopolitical issues | Reduced demand for pharmaceuticals, lower revenue and profitability | Diversify operations and markets. Maintain financial flexibility and strong cash reserves. |
| Regulatory Landscape: | Stringent regulations, evolving compliance requirements | Increased costs, delays in product development and commercialization | Maintain a robust compliance system. Stay updated on regulatory changes and invest in compliance expertise. |
| Debt Levels: | High debt-to-equity ratio | Financial constraints, limited ability to handle unforeseen challenges | Implement debt reduction strategies. Maintain strong cash flow generation. Secure favorable financing terms. |
| Dependence on Key Segments: | Overreliance on specific business segments (e.g., CDMO) | Vulnerabilities to sector-specific challenges | Diversify revenue streams across different segments and markets. Invest in new growth areas. |
| Product Development Risks: | Failure of R&D pipeline, delays in drug approvals | Loss of potential future revenue, impact on investor confidence | Conduct thorough due diligence on R&D pipeline. Focus on high-potential projects with clear market needs. |
| Management Execution: | Ineffective leadership, poor strategic decisions | Negative impact on financial performance, reputational damage | Evaluate management track record and strategic vision. Monitor implementation of key initiatives. |
Piramal Pharma Competitors
| Category | Competitor | Description | Strengths |
|---|---|---|---|
| CDMO: | Lonza: | Swiss multinational chemical and biotechnology company | Strong global presence, diverse capabilities, experience in complex drug development. |
| Contract Pharma: | US-based leading CDMO provider | Established track record, expertise in high-potency APIs and biologics. | |
| WuXi AppTec: | Chinese leading CDMO player | Strong regional presence, competitive cost structure, focus on innovation. | |
| Boehringer Ingelheim: | German pharmaceutical giant with growing CDMO segment | Strong R&D capabilities, integrated drug development expertise. | |
| Critical Care: | Fresenius Kabi: | German multinational healthcare company specializing in infusion therapies and critical care products. | Extensive product portfolio, global distribution network, strong brand recognition. |
| Baxter International: | US-based multinational healthcare company with a strong critical care portfolio. | Established presence in hospitals and clinics, innovative product pipeline. | |
| Pfizer: | US-based pharmaceutical giant with a diverse critical care portfolio. | Strong R&D capabilities, broad market reach, established brand reputation. | |
| Consumer Healthcare: | Dabur India Ltd.: | Leading Indian company with a strong presence in OTCs and personal care products. | Extensive product portfolio, deep understanding of the Indian market, strong brand recognition. |
| Emami Ltd.: | Another leading Indian player in OTCs and personal care products. | Wide range of products, focus on natural ingredients, strong marketing & distribution network. | |
| Zydus Cadila Healthcare Ltd.: | Diversified Indian pharmaceutical company with a growing consumer healthcare segment. | Affordable product offerings, focus on rural markets, established distribution network. |
Piramal Pharma Share Price FAQs
Q: What are the analysts’ expectations for Piramal Pharma’s share price in the future?
A: Analyst estimates for Piramal Pharma’s future share price vary depending on their individual assessment of the company’s prospects. Some analysts predict an upward trend, while others may be more cautious. It’s crucial to research various analyst reports and consider their reasoning before making investment decisions.
Q: Is Piramal Pharma a good investment?
A: This question cannot be definitively answered as it depends on your individual investment goals, risk tolerance, and financial situation. Consider factors like the company’s financial health, future growth potential, competitive landscape, and overall market conditions before making investment decisions.
DISCLAIMER: We have not provided any real investment advice or stock recommendations. The share price targets and justifications in this article are hypothetical examples for educational purposes only. Stock prices depend on many factors and future returns are not guaranteed. Readers should do their own research before investing. Or consult a registered financial advisor for guidance. We do not guarantee any stock performance or returns. Investing in stocks involves risks.
